ResMed Inc. sees soft North American sales but lifts dividend: Should you buy?

The outlook in North America remains clouded, but the group's balance sheet remain strong.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sleep treatment specialist ResMed Inc. (CHESS) (ASX: RMD) today announced flat sales and lower operating profits for the quarter ending June 2014, but saved face with investors by increasing the quarterly dividend 12% to US$2.8 cents per share.

The lower-than-anticipated quarterly results were the result of a worrying sales decline in its key North American markets. Recently selling for $5.50 (US$51.50) the market has been pricing ResMed as a growth stock selling on more than 21 times diluted earnings per shares of US$2.39 for financial year 2014. This growth stock status is likely to come under pressure as the weak North American numbers suggest changes to U.S. Medicare spending and reimbursement patterns have taken their toll.

The overall cost and use of ResMed's Continuous Positive Airway Pressure (CPAP) treatment for sleep apnoea has come under scrutiny in the U.S recently, and the effect now appear to be hitting ResMed's top and bottom line. Overall, ResMed managed to expand gross margin 20 basis points on the same period last year, despite a decline in the average selling price of its products. This thanks to manufacturing improvements, a favourable geographic mix, and favourable exchange rate movements.

With operating profits falling on the prior quarter and a tough outlook in its U.S. market, ResMed will be relying on new product launches and growth outside the Americas in the new financial year to return it to its growth stock status. Of course it's not just North Americans that suffer from sleep apnea and quarterly sales outside the Americas of US$200.3 million almost matched those inside at US$214.9 million. This is notable and illustrates how the global growth story remains a key factor in driving the stock forward.

The company's balance sheet remains strong, allowing it to continue its share buyback program in the most recent quarter and raising a dividend paid in U.S. cents before transfer to Australian investors. Assuming the company maintains the latest payout (US2.8 cents per share), a full-year payout of US11.2c cents per share is likely. This places ResMed on a yield of 2.03% when selling for $5.50. The effective yield will rise for Australian investors if as anticipated the U.S. dollar starts to strengthen over the Australian dollar in the coming year.

The outlook in the Americas remains uncertain, although over the medium and long term ResMed remains a solid prospect assuming it can readjust to the changing dynamics of the North American market. Investors may see price weakness today as an opportunity to buy what remains a promising global growth story over long-term horizons.

Shares look likely to come under selling pressure having closed at $5.50 on Thursday.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »